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Abstract
Background: The aim of the study was to evaluate the effi cacy and safety of small surface 
steroid-eluting atrial and ventricular pacing leads in comparison to non-steroid leads using 
remote monitoring system (Biotronik Home Monitoring®).
Methods: In this randomized multicenter prospective trial, SIELLO T steroid-eluting ven-
tricular leads (n = 42) were compared to BPPU T non-steroid leads (n = 46) and SIELLO 
JT steroid-eluting atrial leads (n = 24) to BPPU JT non-steroid leads (n = 27) (Biotronik, 
Berlin, Germany) in pacemaker devices with remote monitoring capabilities. Lead parameters 
were evaluated during implantation, at 1-week and 1, 3, 6-month outpatient follow-up. Remote 
monitoring data were collected weekly.
Results: Atrial and ventricular steroid-eluting leads had stable sensing and impedance as 
compared to non-steroid leads at implantation and during follow-up. Patients with non-steroid 
atrial leads had signifi cantly higher threshold compared to steroid leads at 1-week and at 
1, 3, 6-month follow-up with a peak at 1-month (1-month 1.4 ± 0.6 vs. 0.7 ± 0.3 V at 0.4 ms, 
p < 0.001; 6-month 0.3 ± 0.5 vs. 0.2 ± 0.3 V at 0.4 ms, p = 0.002). Patients with non-steroid 
ventricular leads had signifi cantly higher threshold compared to steroid leads at 1, 3, 6-month 
(6-month 1.0 ± 0.3 vs. 0.6 ± 0.2 V at 0.4 ms, p < 0.001). Remote monitoring confi rmed con-
sistent results. During the study, 3 patients died of non-lead-related death. Lead repositioning 
was necessary in 2 atrial, 2 ventricular steroid leads and in 1 ventricular non-steroid lead.
Conclusions: Atrial and ventricular pacemaker leads with steroid showed signifi cantly lower 
pacing threshold compared to non-steroid leads, confi rmed by remote monitoring. (Cardiol J 
2013; 20, 4: 431–438)
Key words: steroid-eluting pacing leads, atrial pacing lead, ventricular pacing 
lead, remote monitoring, steroid
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Introduction
Rising pacing threshold after implantation is 
a well-known phenomenon in endocardial pacing, 
caused by formation of a fi brotic capsule at the 
lead-tissue interface due to infl ammatory reactions 
[1]. Use of anti-inflammatory drugs like dexa-
methasone has been established for many years to 
suppress acute and chronic cellular infl ammation 
and release of infl ammatory mediators, resulting 
in lower pacing threshold and pacing energy [1, 2]. 
With the development of pacemaker (PM) the-
rapy, rate responsive sensors and enhanced diagno-
stic features necessitated the improvement of lead 
technology to reduce current drain and extend PM 
longevity [3]. Small surface, high-impedance pacing 
leads were able to decrease current drain, however 
the smaller surface area was initially associated 
with worse sensing capabilities and higher pacing 
threshold. Several studies have proven the bene-
fi cial short and long-term effects of steroid pacing 
leads [4–7], however, no study  has been conducted 
yet to directly compare small surface endocardial 
pacing leads with or without steroid-eluting collar 
with other with identical shape and structure.
Home Monitoring® is an established remo-
te monitoring system providing remote patient 
follow-up and monitoring while using automatic 
wireless communication and home transmitters. 
It is a reliable method to effectively reduce ho-
spital visits [8, 9], hospital visit related costs and 
improve patient safety [10, 11]. The use of remote 
monitoring system has not yet been established 
to follow-up acute and chronic lead performance 
in PM patients with steroid or non steroid-eluting 
leads.
This randomized, multicenter clinical study 
was designed to compare small porous surface 
atrial and ventricular pacing leads with same shape 
and structure, with 0.27 mg of dexamethasone 




Patients included in the analysis were con-
secutively selected from 3 investigational inter-
national centers (2 centers in Germany, 1 center 
in Hungary) based on pre-specifi ed inclusion and 
exclusion criteria. Inclusion criteria included 
patients with standard PM indication referred to 
the hospital if they were geographically stable and 
available for follow-up visits at the center. Patients 
were excluded if they had life expectancy of less 
than 6 months, planned cardiac surgery in the next 
6 months, enrolled in another cardiac clinical in-
vestigation or had other medical devices that may 
have had an interaction with the implanted PM. 
The clinical investigation was conducted accor-
ding to the ethical principles of the Declaration of 
Helsinki (2008) and ISO 14155 Clinical Investiga-
tion of Medical Devices (Part I and II 2003). The 
study protocol was approved by the International 
Ethics Committee (Freiburger Ethik-Kommission 
International, FEKI) in Germany and by the local 
Institutional Review Board (IRB) in Hungary. All 
patients provided informed consent before the 
enrollment. From October 2009 to August 2010, 
88 patients were implanted with study investigatio-
nal leads and conventional PM devices capable of 
remote monitoring. Six drop-outs occurred during 
the duration of the study due to patient death or 
loss of contact.
Investigational leads
The SIELLO T/JT leads are a family of 5.9 F, 
steroid-eluting, transvenous, endocardial bipolar 
passive-fi xation leads. The SIELLO T is a straight 
lead, while the SIELLO JT carries a J-shaped distal 
end. The SIELLO T lead is available in 53 cm and 
60 cm length, while the SIELLO JT lead varies 
in lengths of 45 cm and 53 cm. The leads have an 
isodiametric structure and silicone insulation. The 
inner and outer conductors consist of quadruple 
wire coils. They are covered by polyurethane 
overlay for better gliding. The SIELLO T/JT 
leads have an IS-1 connector and a 12 mm pole 
distance. The SIELLO T/JT electrode tip has 
a fractal iridium coating and an active surface area of 
2.1 mm2. The ring electrode has a surface of 17.4 mm2 
and is coated with iridium. The leads carry 4 tines 
for passive fi xation. The SIELLO T/JT leads have 
a dexamethasone eluting steroid collar with a total 
amount of 0.27 mg DXA.
The BPPU T/JT leads are completely identical 
in shape and structure to the SIELLO T/JT leads 
but not featuring steroid eluting collar. Instead of 
the steroid eluting collar, there is a pure silicone 
dummy collar mounted with the same dimensions 
as the steroid eluting collar of the SIELLO T/JT 
leads. 
Randomization procedure
Patients were randomized in a 1:1 fashion to 
receive either steroid-eluting SIELLO T/JT inve-
stigational lead or non-steroid BPPU T/JT investi-
gational lead with the same shape and structure. 
www.cardiologyjournal.org 433
Valentina Kutyifa et al., Study to compare steroid, non-steroid leads
After patient enrollment, a sealed randomization 
envelope was assigned to the patient. The study 
was not structured to be blinded, the randomization 
envelope was opened by the study personnel and 
both the implanting physician and patients were 
aware of the treatment assignment.
Device and lead implantation procedure
All patients had undergone conventional 
transvenous PM implantation based on current 
standards. Commercially available single and dual 
chamber PM devices (Biotronik) were used in the 
study with remote monitoring capabilities availab-
le. Lead and device testing during the implanta-
tion procedure was performed based on accepted 
standards. No additional test was required by the 
study protocol.
Device programming
Devices were programmed to AAI(R), VVI(R) 
or DDD(R) mode depending on the leads and PM 
implanted. Devices with Home Monitoring® avai-
lable were recommended to program it ON, unless 
not eligible for the patient. 
Patient follow-up, device interrogation
Patients had an ambulatory follow-up within 
1-week after device implantation (pre-discharge 
testing) and 1, 3, 6-month thereafter until the end 
of the trial or in case of an adverse event. The mean 
follow-up time of the study was 6 months. Home 
Monitoring® data were received and evaluated in 
patients with remote monitoring on a daily basis. 
Interrogation data at regular follow-up procedures 
and at any device-related adverse events were 
sent to the interrogation core laboratory in Berlin, 
Germany for further evaluation.
Defi nitions and study endpoints
The primary end point of the study was the 
effi cacy assessment of SIELLO T/JT leads suppor-
ted by the collection of measured data (sensing, 
pacing impedance, and pacing threshold) during 
the implantation and follow-up procedures with 
special focus on the atrial and ventricular threshold 
evaluated at 0.4 ms impulse width and compared to 
the non-steroid BPPU T/JT leads. The secondary 
endpoint was lead safety data on adverse events 
collected during the entire study duration.
Statistical analysis
Continuous variables are expressed as mean 
± standard deviation. Categorical data are sum-
marized as frequencies and percentages. The ran-
domization process was carried out using PROC 
PLAN in SAS with a block length of 6. The lead 
evaluation data were compared between patient 
groups of steroid-eluting and non steroid-eluting 
pacing leads, T-test for independent samples or 
Mann-Whitney-U test was used, as appropriate. 
All tests were 2-sided and a p-value of < 0.05 was 
considered statistically signifi cant.
Results
Steroid or non-steroid eluting leads were im-
planted in 88 patients (35 female) with the mean 
age of 72.9 ± 10.1 years in the steroid-eluting lead 
group (42 patients) and 73.4 ± 9.1 years in the non 
steroid-eluting lead group (46 patients).
Clinical characteristics
Patients with implanted non-steroid lead had 
trend towards more frequent valvular disease 
(30.4% vs. 16.7%, p = 0.130) and cardiomyopathy 
(17.4% vs. 7.4%, p = 0.147). Incidence of hyper-
tension, diabetes mellitus and renal insuffi ciency 
and drug treatment was similar in both groups 
(data not shown).
Indication of permanent PM therapy is sum-
marized in Table 1. Twenty (47.6%) patients with 
steroid-eluting leads and 16 (34.8%) patients with 
Table 1. Indications of permanent pacemaker therapy.
Indications SIELLO T/JT (n = 42)* BPPU (n = 46)* Total (n = 88)*
Intermittent or complete AVB 18 (42.9%) 19 (41.3%) 37 (42.0%)
Sinus node arrest, symptomatic bradycardia 20 (47.6%) 16 (34.8%) 36 (40.9%)
Sinoatrial block 1 (2.4%) 2 (4.3%) 3 (3.4%)
Chronotropic incompetence 2 (4.8%) 2 (4.3%) 4 (4.5%)
Atrial tachycardia 7 (16.7%) 7 (15.2%) 14 (15.9%)
Other (indication) 12 (28.6%) 18 (39.1%) 30 (34.1%)
*Due to multiple selections the quantities do not sum to the total of patients; AVB — atrioventricular block; Other — indication was not 
specified
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non-steroid leads had symptomatic sinus arrest at 
baseline. Intermittent or complete atrioventricu-
lar block was present in 18 (42.9%) patients with 
steroid-eluting leads and 19 (41.3%) patients with 
non-steroid leads. 
Lead and device implantation procedure
Implantation of right atrial leads was primarily 
performed via left cephalic access (60.9%), less 
often via the subclavian vein (39.1%). Ventricular 
leads were implanted via the left or right cephalic 
vein (57.8%), less often via the left or right subc-
lavian vein (42.2%).
The distribution of implanted leads per patient 
and implanted PM models are summarized in Table 2. 
Non-steroid BPPU JT atrial lead and BPPU T 
ventricular leads were implanted in 30.7% of the 
patients, while steroid-eluting SIELLO JT atrial 
lead and SIELLO T ventricular lead were present in 
27.3% of the patients. Single-chamber devices and 
ventricular lead only with steroid-eluting tip were 
implanted in 3.4% of the patients, in 5.7% with no 
steroid tip. Both study and non-study leads were 
implanted in 15.9% and 17.0% of the total patient 
population, respectively.
The ventricular lead position was apical in 
45.2% of steroid eluting leads and 43.5% of non-
-steroid leads, while septal in 54.8% of steroid-
-eluting leads and 56.5% of non-steroid leads. 
The atrial lead was implanted at the right atrial 
appendage in all patients.
Lead implantation procedure as assessed by 
the implanting physician was very easy or easy 
in all atrial leads (100%), while declared to be the 
same in 96.5% of ventricular leads. Moderately 
diffi cult or diffi cult implantation of the ventricular 
leads of either type was reported in 3.5% of the 
total patient population.
The total fl uoroscopy time was 2.8 ± 2.7 min 
(median: 1.8, minimum: 0.1, maximum: 8.0) in sin-
gle atrial or ventricular lead implantations, while 
4.1 ± 3.4 min (median: 3.0, minimum: 0.3, maxi-
mum: 18.5) in case of dual chamber devices. The 
procedure time was 26.4 ± 8.3 min (median: 22.5, 
minimum: 19.0, maximum: 40.0) for single chamber 
PM and 28.0 ± 13.8 min (median: 27.0, minimum: 
8.0, maximum: 75.0) for dual chamber PM.
Evaluation of lead integrity and 
lead parameters, device longevity
Atrial lead integrity parameters and sensing 
function evaluated at implantation, pre-discharge 
follow-up and at 1, 3, 6 months follow-up proce-
dures were within normal limits in steroid and 
non-steroid eluting atrial leads. There was a sig-
nifi cant difference found steroid-eluting and non 
steroid-eluting atrial leads in the pacing impedance 
at 1-month follow-up (1-month 774 ± 91 vs. 700 ±
± 111 Ohm, p = 0.012). 
The atrial threshold was signifi cantly higher in 
non-steroid leads as compared to steroid-eluting le-
ads at 1-week and at 1, 3 and 6 month follow-up with 
a peak at 1-month (1-month 1.4 ± 0.6 vs. 0.7 ± 0.3 V at 
0.4 ms, p < 0.001) (Table 3). The mean value of atrial 
threshold in non-steroid leads was increasing until 
the 3-month follow-up, and slightly decreasing until 
the 6-month follow-up, then remained stable (Fig. 1).
Ventricular steroid-eluting leads had stable 
and similar sensing and lead impedance as compa-
red to non-steroid leads at implantation and during 
follow-up. The ventricular pacing impedance was 
slightly higher in steroid-eluting leads at pre-
-discharge follow-up as compared to non-steroid-
-eluting ventricular leads (911 ± 138 vs. 840 ± 
± 128 Ohm, p = 0.015). Patients with non-steroid 
ventricular leads had signifi cantly higher threshold 
compared to steroid-eluting leads at 1, 3, 6-month 
follow-up visits with clear early separation at 
1 month, remaining stable at the 6-month follow-
-up (6-month 1.0 ± 0.3 vs. 0.6 ± 0.2 V at 0.4 ms, 
p < 0.001) (Table 3). 
Table 2. Distribution of implanted leads per 
patient and implanted pacemaker models.
Leads
BPPU JT and BPPU T 27 (30.7%)
SIELLO JT and SIELLO T 24 (27.3%)
SIELLO T and non-study 
RA lead
15 (17.0%)
BPPU T and non-study 
RA lead
14 (15.9%)
BPPU T only 5 (5.7%)
SIELLO T only 3 (3.4%)
Total 88 (100%)
Pacemaker model
Philos II SR 5 (5.7%)
Philos II DR 13 (14.8%)
Philos II DR-T 19 (21.6%)
Cylos VR 1 (1.1%)
Cylos DR 3 (3.4%)
Cylos 990 SR 2 (2.3%)
Cylos 990 DR 13 (14.8%)
Cylos 990 DR-T 30 (34.1%)
Evia DR-T 2 (2.3%)
Total 88 (100%)
All pacemaker devices manufactured by Biotronik SE & Co. KG, 
Berlin, Germany and have valid CE-certificate.
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Home Monitoring® data of steroid-eluting and 
non-steroid ventricular lead performance were ava-
ilable in 51 (58%) patients implanted with ventri-
cular steroid or non-steroid leads. Figure 1 shows 
ventricular threshold data at on-site follow-up vi-
sits, as well as weekly Home Monitoring® data. We 
found excellent correlation between on-site follow-
-up visit assessments and Home Monitoring® data 
Table 3. Atrial and ventricular pacing threshold of SIELLO JT and BPPU JT leads.





























































































PHD — pre-discharge testing; FU — follow-up; SD — standard deviation
Figure 1. Ventricular pacing threshold values provided by Home Monitoring® (HM) and measured at on-site follow-
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provided (3-month correlation coeffi cient = 0.88, 
p < 0.001, 6-month = 0.89, p < 0.001).
We also calculated the device longevity for the 
steroid vs. non-steroid-eluting ventricular leads, 
using the standard programming of VVI 60 bpm, 
100% pacing, and a stimulation pulse width of 0.4 ms. 
Patients implanted with a steroid-eluting lead had 
2 ± 5 months additional device longevity, depen-
ding on the type of the implanted PM.
Adverse events
A total of 45 adverse events (0.51 events/
/patient) have been reported during the duration 
of the study. All adverse events are sorted by 
underlying cause and severity, as adverse event 
(AE) or serious adverse event (SAE) in Table 4. 
Two-thirds of AE’s was classified as SAE. Seven 
AE’s were reported as cases of atrial fibrillation. 
One AE was reported with symptoms of chro-
notropic incompetence, device reprogramming 
eliminated the symptoms. A total of 10 lead 
related adverse device effects occurred, 5 of 
them were resolved by PM reprogramming. Four 
SIELLO T/JT lead and 1 BPPU T/JT lead required 
lead reposition procedure during the study, all 
of the lead dislodgements occurred in the early 
postoperative period (BPPU T non-steroid lead 
1 day after implantation, SIELLO T/JT steroid 
leads 0–2 days after implantation). During the 
follow-up 3 patients died, without any relation 
to the investigational study leads (1 of sepsis, 
1 of multiple organ failure and 1 of sudden car-
diac death).
Discussion
To our knowledge, this is the fi rst randomized 
multicenter study directly comparing steroid-
-eluting and non-steroid eluting small surface atrial 
and ventricular lead performance. Our study de-
monstrated that atrial and ventricular small surface 
pacing leads with steroid collar had signifi cantly 
lower pacing threshold compared to non-steroid 
leads. Both leads were safe and effi cient as addi-
tionally confi rmed by Home Monitoring®.
Previous studies have shown that standard 
steroid-eluting pacing leads either with dexametha-
sone acetate or phosphate compound effi ciently 
reduce the pacing threshold rise after implantation 
caused by infl ammatory reactions at the tissue-
-lead interface [1, 7, 12]. This effect was stable 
and maintained during 5-or 10-year follow-up [13, 
14]. Similarly benefi cial effects of steroid-eluting 
coating were observed in active fixation atrial 
pacing leads [15].
Small surface, higher impedance pacing leads 
were able to reduce battery current drain, however 
the small surface area was associated with worse 
sensing capabilities and higher pacing threshold 
[16, 17]. Therefore, there is a rationale to use ste-
roid eluting surface in small surface pacing leads.
The main fi nding of the current study was that 
patients with non steroid-eluting atrial leads had 
signifi cantly higher threshold compared to steroid-
-eluting leads at 1-week and 1, 3 and 6-month 
follow-up. Consistent with these fi ndings, patients 
with non-steroid ventricular leads showed signi-
fi cantly higher thresholds compared to steroid-
-eluting pacing leads at 1, 3, 6-month follow-up. 
Previous clinical studies showed similar results 
when comparing steroid-eluting conventional 
surface electrodes with non-steroid-eluting leads 
[18] or when comparing high-impedance steroid 
eluting leads with conventional surface steroid-
-eluting leads [5].
Additional strength of this trial is that remote 
Home Monitoring® system was proven to be effi -
cient, following changes in ventricular threshold 
 Table 4. Adverse events and serious adverse events.
Category Adverse event Serious adverse event All 
Patient death: cardiac 0 (0.0%) 1 (3.3%) 1 (2.2%)
Patient death: non-cardiac 0 (0.0%) 2 (6.7%) 2 (4.4%)
Right atrial lead related 3 (20.0%) 2 (6.7%) 5 (11.1%)
Right ventricular lead related 2 (13.3%) 3 (10.0%) 5 (11.1%)
Procedure related 1 (6.7%) 1 (3.3%) 2 (4.4%)
Medical 4 (26.7%) 18 (60.0%) 22 (48.9%)
Arrhythmias 4 (26.7%) 3 (10.0%) 7 (15.6%)
Pacemaker therapy related 1 (6.7%) 0 (0.0%) 1 (2.2%)
Total 15 30 45
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parameters with an excellent correlation (r = 0.89 
at 6-month, p < 0.001). This might have important 
clinical implications in the future. Previous studies 
showed that Home Monitoring® effectively iden-
tifi ed PM patients in need for in-offi ce follow-up 
[8], reduced follow-up visits [8] and shortened 
the length of hospital stay at implantation [9]. It 
reduced hospitalizations caused by atrial arrhyth-
mias and related strokes, improved patient safety 
and outcomes, while maintained quality of life [8]. 
Patients using the Home Monitoring® system were 
generally satisfi ed with the system [10]. The use 
of a remote monitoring system has not yet been 
established to follow-up acute and chronic lead 
performance in PM patients with steroid or non 
steroid-eluting leads. Patients with high pacing 
threshold at implantation might benefi t from im-
plantation of a PM with remote monitoring capa-
bilities by reducing in-hospital stay and improving 
patient safety.
During the course of the trial four SIELLO T/
/JT lead and 1 BPPU T/JT leads had dislodgements, 
however all the dislodgements occurred in the 
early postoperative period, within the fi rst 2 days 
after implantation. Given the time frame of the lead 
dislodgements, they are considered to occur due 
to the technical challenge of implanting this new 
type of electrodes, and not specifi cally attributed 
to the steroid coating.
The calculated device longevity indicated, 
that the implantation of a steroid-eluting lead is 
associated with a longer battery life, therefore re-
placement is less often needed, which has already 
been suggested earlier [15].
A potential limitation of our study might be 
the relatively small number of atrial leads implan-
ted. Additionally, these leads were small surface 
leads, but the pacing impedance did not exceed 
1000 Ohm. Remote monitoring was not available 
for atrial leads during the conduction of the cur-
rent study however we assume that the excellent 
agreement with remote and on-site follow-up for 
ventricular leads might be similar for atrial leads. 
Longer-term follow-up is needed to further evalu-
ate pacing threshold in patients with non-steroid 
leads, which might rise after 6 months.
Conclusions
This randomized, multicenter, large cohort 
study demonstrated that steroid-eluting atrial and 
ventricular small surface PM leads have signifi -
cantly lower pacing threshold as compared to non 
steroid-eluting atrial and ventricular leads with 
the same shape and structure. Both leads were 
proven to be effi cient and safe. Ventricular lead 
performance was additionally confi rmed by remote 
monitoring (Home Monitoring®).
Clinical Trial Registration: URL: http://clinical-
trials.gov. Unique identifi er: NCT01000532.
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